Pharma localization in Saudi Arabia, visualized.
Vision 2030 is pulling pharma manufacturing into the Kingdom with a 10% local-content price preference, a Mandatory List that can shut imports out of government tenders, and the National Biotechnology Strategy. Here is the whole picture — the procurement lever, the import-to-tech-transfer spectrum, PIF's CDMO Lifera, and the call on whether to localize.
Locally made vs imported
Like the RHQ program, localization runs on a carrot and a stick. The carrot is a 10% price preference and a faster regulatory lane; the stick is a 10% handicap in every government tender — and exclusion where your category sits on the Mandatory List. Here is what changes either way.
| Dimension | Locally manufactured | Imported |
|---|---|---|
| Government-tender price | Scored as-is — the competing foreign bid is marked up 10% against you (S1) | Carries a 10% scoring handicap versus a national product (S1) |
| Mandatory-List items | Eligible — pharma & medical preparations are now on the list (S2) | Barred where a national product exists on the Mandatory List (S2) |
| SFDA registration | Access to SFDA incentives: priority registration, pricing flexibility, reduced fees (S7) | Standard registration pathway & fees |
| NUPCO procurement | Preferential treatment for locally-manufactured / local-partner supply (advisory) | Competes without the local-content edge |
| Vision 2030 alignment | Counts toward the 40% pharma-localization goal & biotech strategy (S4 · S5) | Outside the localization narrative |
| Strategic signal | A committed manufacturing partner in the Kingdom | A transactional importer |
From ~20% to 40% of value
Vision 2030's industrial program (NIDLP) targets localizing 40% of the value of the pharmaceutical industry— roughly a doubling of today's domestic share. That gap is the commercial opening every multinational is being pulled toward.
Four forces pulling pharma local
Procurement law is the immediate driver; the Mandatory List makes it compulsory for listed items; the SFDA rewards it; and Vision 2030 puts national capital behind it.
- In government tenders, a competing foreign bid is treated as 10% more expensive than a national product (S1)
- Set by primary law — Council of Ministers Resolution 245 (2019)
- On a thin tender margin, that 10% routinely decides the award
- The Mandatory List names products that state entities are required to source locally (S1)
- Pharmaceuticals & medical preparations were added in 2025 — 105 products, 7 sectors (S2)
- Expected government spend on the new items exceeds SAR 2.3 billion (S2)
- SFDA's incentive list offers priority in registration & pricing flexibility (S7)
- Support and exemption from some technical requirements; reduced registration & inspection fees (S7)
- Locally-manufactured products are reported to clear approval faster than imports (advisory)
- NIDLP targets localizing 40% of the value of the pharmaceutical industry (S4)
- The National Biotechnology Strategy (Jan 2024) targets local biologics, biosimilars & vaccines (S5)
- PIF's CDMO, Lifera, exists to localize the hard-to-make medicines (S8)
From import to tech transfer
"Localized" is not one thing — it is a ladder of deepening in-Kingdom value. Most multinationals enter low and climb: AstraZeneca began with secondary packaging and progressed to full local manufacture of about half its small-molecule portfolio.
Finished product made abroad and registered for sale. No local content — the default, and the position the price preference penalizes.
Bulk product is imported, then labelled and packed in the Kingdom. The lightest local-content step — where AstraZeneca started before moving up (S11).
The drug substance is imported but filled, finished and quality-released locally. Common for sterile injectables and a typical first real manufacturing footprint.
End-to-end production in the Kingdom. AstraZeneca moved to full local manufacture of ~50% of its small-molecule portfolio (nine SKUs) ahead of schedule (S11).
Transferring know-how — including biologics, biosimilars and vaccines — and building development capability. The deepest rung, and the explicit aim of the biotech strategy and Lifera's partnerships (S5 · S9).
"Depth" here is an illustrative ladder of in-Kingdom value added, not an official scale — Saudi Arabia measures local content by the share of value added locally, but does not publish a numbered pharma-specific tier table. Treat the rungs as industry-practice stages. to verify
Lifera & the tech-transfer route
You do not have to build a plant to localize. Lifera, the Public Investment Fund's contract development & manufacturing company (CDMO), exists to localize the hard-to-make medicines — biologics, vaccines, insulins and plasma — and is signing tech-transfer partnerships with multinationals. These are the sourced deals to date.
| Partners | What is being localized | Date |
|---|---|---|
| Lifera ↔ Novo Nordisk | Localize over 50% of Saudi Arabia's insulin needs (via SaudiBio); first biologic-innovator insulin in the GCC by 2027. S9 | Oct 2024 |
| Lifera ↔ Novo Nordisk | Enable local production of semaglutide (GLP-1) treatments in the Kingdom. S10 | Apr 2025 |
| Sanofi ↔ Arabio ↔ Lifera | Three-way MoU for vaccine manufacturing in Saudi Arabia, with Lifera as contract manufacturer. S13 | Jul 2023 |
| AstraZeneca ↔ SPIMACO | Technology-transfer of 5 products / 11 SKUs (~SR 300m a year); later progressed to full local manufacture of ~50% of the small-molecule portfolio. S12·S11 | 2018 → 2025 |
Lifera is a PIF company focused on localizing biopharmaceutical production (S8). The partnerships above are each sourced to a company announcement or reputable trade report — several are MoUs or non-binding term sheets at the time of writing, so confirm current status directly. No public investment figure or capacity target for Lifera itself has been disclosed; do not assume one.
The bar — and the obligations
The preference rewards genuine in-Kingdom value, not a relabelled import. Local content is measured by the share of value actually added in Saudi Arabia. This is the practical bar to clear.
From business case to national product
Localization is a sequence, not a switch. The economics start with your government-revenue exposure; the build starts with picking a rung. Steps marked gate are the ones that actually decide it.
Map how much of your KSA revenue runs through NUPCO / government tenders, now and in plan. The localization economics turn on that public-sector share — exactly the RHQ question, one layer down.
Decide where to enter: secondary packaging, fill-finish, full manufacture or tech transfer. Match the rung to your volume, product complexity and time horizon.
Build your own plant, form a JV with a local manufacturer (e.g. SPIMACO, Tabuk, Jamjoom), or contract a CDMO such as PIF-owned Lifera.
Register the locally-manufactured product so it counts as a national product — and tap the SFDA incentive lane: priority registration, pricing flexibility and reduced fees (S7).
Position the product to benefit from the 10% price preference and, where applicable, Mandatory-List status in government procurement.
Move up the rungs — add SKUs, raise the in-Kingdom value share, and build toward tech transfer. The incentives reward depth, not a one-time gesture.
Should you localize?
One question dominates the decision — the same one that drives the RHQ call, a layer deeper: how much of your Saudi revenue depends on the government channel?
- The 10% preference compounds across every tender
- Mandatory-List items may be off-limits to imports
- Start at packaging/fill-finish and climb
- Plant capex & GMP overhead can exceed the tender upside
- A CDMO (Lifera) lets you localize without owning bricks
- Watch the Mandatory List — your category could be added next
The pharma & RaqibHealth angle
Localization and the regional-HQ decision are two halves of the same KSA market-access play — and both turn on live SFDA & procurement intelligence. This guide pairs with the Saudi RHQ guide.
Where the facts come from
Official Saudi sources (the MOF procurement regulation, LCGPA, SPA, Vision 2030, SFDA, NUPCO) are marked in green — the 10% price preference is primary law and the Mandatory List adding pharmais confirmed by SPA. Localization-deal and practice points carried by company announcements or trade press are marked accordingly, and any advisory-only claim carries a "to verify" marker on-page.
This guide is informational and not legal, regulatory or tax advice. Saudi local-content rules, the Mandatory List, procurement preferences, SFDA incentives and localization partnerships change frequently — always confirm against the Local Content & Government Procurement Authority (LCGPA), NUPCO, the SFDA and a qualified Saudi advisor before acting. RaqibHealth cites its sources on every record. info@raqibhealth.com · RaqibHealth home